Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
2.
Sci Rep ; 9(1): 14551, 2019 10 10.
Article in English | MEDLINE | ID: mdl-31601938

ABSTRACT

Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences necessitating multiple surgeries. Imatinib mesylate (IM) blocks the CSF-1 receptor. This study investigated the long term effects of IM in TGCT. We conducted an international multi-institutional retrospective study to assess the activity of IM: data was collected anonymously from individual patients with locally advanced, recurrent or metastatic TGCT. Sixty-two patients from 12 institutions across Europe, Australia and the United States were identified. Four patients with metastatic TGCT progressed rapidly on IM and were excluded for further analyses. Seventeen of 58 evaluable patients achieved complete response (CR) or partial response (PR). One- and five-year progression-free survival rates were 71% and 48%, respectively. Thirty-eight (66%) patients discontinued IM after a median of 7 (range 1-80) months. Reported adverse events in 45 (78%) patients were among other edema (48%) and fatigue (50%), mostly grade 1-2 (89%). Five patients experienced grade 3-4 toxicities. This study confirms, with additional follow-up, the efficacy of IM in TGCT. In responding cases we confirmed prolonged IM activity on TGCT symptoms even after discontinuation, but with high rates of treatment interruption and additional treatments.


Subject(s)
Antineoplastic Agents/therapeutic use , Giant Cell Tumor of Tendon Sheath/drug therapy , Imatinib Mesylate/therapeutic use , Adult , Australia , Disease Progression , Disease-Free Survival , Europe , Female , Humans , Middle Aged , Neoplasm Metastasis , Receptors, Colony-Stimulating Factor/antagonists & inhibitors , Retrospective Studies , Treatment Outcome , United States
3.
Br J Cancer ; 110(10): 2420-6, 2014 May 13.
Article in English | MEDLINE | ID: mdl-24736584

ABSTRACT

BACKGROUND: There are neither prospective data nor agreement on the optimal routine follow-up procedures in patients treated for soft tissue sarcoma of the limb. METHODS: Data on 174 consecutive patients with a soft tissue sarcoma of the limb undergoing follow-up by oncologists at a single centre from 2003 to 2009 were included in this analysis. The rate and site of recurrence and mode of detection were analysed. Outcome of the patients was assessed. RESULTS: Eighty-two patients (47%) experienced relapse of any type. Isolated local recurrence occurred in 26 patients and local relapse with synchronous pulmonary metastases in five patients. Local recurrences were detected clinically in 30 of these 31 patients; magnetic resonance imaging identified only one local recurrence. Twenty-eight patients developed isolated lung metastases; in nine patients these were amenable to resections, seven of whom are currently free of disease after treatment. Lung metastases were detected by chest x-ray (CXR) in 19 patients, computed tomography scanning in 3 patients, and clinically in 11 patients. Twenty-three patients developed non-pulmonary metastases. More than 80% of relapses occurred in the first 2 years of follow-up; however, later recurrences were also observed. CONCLUSIONS: Routine follow-up CXR can detect lung metastases suitable for surgical resection, although the optimal interval of imaging has yet to be defined. Local relapse is almost always detected by patients or physicians, and routine scanning of the primary site is of doubtful benefit. Patient and physician education to detect local relapse may be helpful. Prospective evaluation of follow-up is recommended.


Subject(s)
Extremities/pathology , Sarcoma/epidemiology , Soft Tissue Neoplasms/epidemiology , Adolescent , Adult , Aged , Chemotherapy, Adjuvant , Combined Modality Therapy , Disease-Free Survival , Extremities/surgery , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/epidemiology , Lung Neoplasms/secondary , Lung Neoplasms/surgery , Male , Middle Aged , Neoplasm Recurrence, Local/diagnosis , Radiotherapy, Adjuvant , Retrospective Studies , Sarcoma/secondary , Sarcoma/therapy , Soft Tissue Neoplasms/therapy , Time Factors , Tomography, X-Ray Computed , Treatment Outcome , Young Adult
4.
Eur J Surg Oncol ; 40(4): 394-401, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24534361

ABSTRACT

AIMS: To evaluate tumour volume changes after preoperative radiotherapy (PRT) for borderline operable soft tissue sarcomas (STS). MATERIALS AND METHODS: A retrospective review was performed of 68 patients who received PRT between December 2004 and July 2011. Endpoints were radiological response, surgical margins, local control and survival. RESULTS: Median tumour size was 12.5 cm. Tumour location was extremity (87%), trunk (12%), and neck (1%). Commonest histological subtypes were myxoid liposarcoma (32%) and myxofibrosarcoma (16%). The majority of patients (88%) received 50 Gy in 25 fractions. Post-radiotherapy imaging was available in 55 cases. By RECIST there was stable disease in 89%, partial response in 7% and progressive disease in 4%. Tumour volumes reduced in 80%. Median change in maximal tumour dimension was -13.6%; median change in volume was greater, at -33.3%. Tumour volumes increased in 11 cases (20%). However, surgical margins were clear in all 11 cases, with no local recurrences in this group. For the entire group, surgical margins were clear in 93%, and microscopically positive in 7%. Eight patients (12%) had local relapse at 2-24.8 months after surgery. Two year local relapse free survival was 87.5%; 2 year overall survival was 74.7%. CONCLUSION: The majority of tumours showed reduction in volume. A small number of tumours increased in volume, but there was no definite relationship between volume increase and poor surgical outcomes or lower local control rates. Local control was equivalent to published series' of PRT. PRT is a reasonable approach in patients with borderline resectable tumours.


Subject(s)
Neoadjuvant Therapy/methods , Sarcoma/pathology , Sarcoma/radiotherapy , Adolescent , Adult , Aged , Aged, 80 and over , Dose Fractionation, Radiation , Extremities , Female , Humans , Liposarcoma, Myxoid/pathology , Liposarcoma, Myxoid/radiotherapy , Male , Middle Aged , Neoplasm, Residual/radiotherapy , Neoplasm, Residual/surgery , Radiotherapy, Adjuvant , Retrospective Studies , Sarcoma/surgery , Torso , Treatment Outcome
5.
Eur J Cancer ; 50(2): 388-96, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24215845

ABSTRACT

AIM: Brostallicin is a DNA minor groove binder that has shown activity in patients with soft tissue sarcoma (STS) failing first-line therapy. The present study assessed the safety and efficacy of first-line brostallicin in patients with advanced or metastatic STS >60 years or not fit enough to receive combination chemotherapy. A prospective explorative pharmacogenetic analysis was undertaken in parallel. METHODS: Patients were randomised in a 2:1 ratio between IV brostallicin 10mg/m(2) and doxorubicin 75 mg/m(2) once every 3 weeks for a maximum of six cycles. Disease stabilisation at 26 weeks (primary end-point) was considered a 'success'. Further testing of brostallicin was warranted if ≥ 35 'successes' were observed in the first 72 eligible patients treated with brostallicin. In addition, patients were genotyped for glutathione S transferase (GST) polymorphisms. RESULTS: One hundred and eighteen patients were included (79 brostallicin and 39 doxorubicin). Brostallicin was well tolerated in comparison to doxorubicin with less grade 3-4 neutropenia (67% versus 95%), grade 2-3 systolic dysfunction (0% versus 11%), alopecia (17% versus 61%) and grade 2-3 mucositis (0% versus 18%). For brostallicin versus doxorubicin, 'successes' were observed in 5/77 versus 10/36, progression free survival at 1 year was 6.5% versus 15.6%, objective response rate was 3.9% versus 22.2% and overall survival at 1 year was 50.5% versus 57.9%, respectively. Only GSTA1 genotype was significantly associated with success rate of doxorubicin treatment. CONCLUSION: Brostallicin cannot be recommended at this dose and schedule in this patient population as first-line therapy. GSTA1 genotype may be predictive for doxorubicin efficacy but warrants further study.


Subject(s)
Bone Neoplasms/drug therapy , Doxorubicin/therapeutic use , Guanidines/therapeutic use , Pyrroles/therapeutic use , Sarcoma/drug therapy , Adult , Antibiotics, Antineoplastic/therapeutic use , Bone Neoplasms/genetics , Bone Neoplasms/pathology , Disease-Free Survival , Drug Administration Schedule , Europe , Gene Frequency , Genotype , Glutathione Transferase/genetics , Humans , Isoenzymes/genetics , Kaplan-Meier Estimate , Middle Aged , Neoplasm Metastasis , Pharmacogenetics , Polymorphism, Genetic , Sarcoma/genetics , Sarcoma/pathology , Treatment Outcome
6.
Clin Oncol (R Coll Radiol) ; 19(4): 265-8, 2007 May.
Article in English | MEDLINE | ID: mdl-17433971

ABSTRACT

Tumour-related hypoglycaemia is a rare paraneoplastic phenomenon most frequently occurring with insulinomas, but also associated with non-islet cell tumours. It has been observed in a range of tumour types, but recently a small number of cases have been described in association with gastrointestinal stromal tumours. We describe a further case of a patient with gastrointestinal stromal tumour that was complicated by non-islet cell tumour hypoglycaemia, and discuss the mechanisms and management of non-islet cell tumour hypoglycaemia in the context of gastrointestinal stromal tumour.


Subject(s)
Abdominal Neoplasms/diagnosis , Gastrointestinal Stromal Tumors/diagnosis , Hypoglycemia/diagnosis , Jejunal Neoplasms/diagnosis , Neoplasm Recurrence, Local/diagnosis , Abdominal Neoplasms/complications , Abdominal Neoplasms/secondary , Adult , Diagnosis, Differential , Fatal Outcome , Gastrointestinal Stromal Tumors/complications , Gastrointestinal Stromal Tumors/secondary , Humans , Hypoglycemia/complications , Hypoglycemia/pathology , Insulin-Like Growth Factor II/metabolism , Jejunal Neoplasms/complications , Jejunal Neoplasms/pathology , Male , Neoplasm Metastasis , Neoplasm Recurrence, Local/complications , Neoplasm Recurrence, Local/pathology
7.
Clin Oncol (R Coll Radiol) ; 17(5): 385-90, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16097572

ABSTRACT

Radiation myelopathy is a rare, devastating, late effect of radiotherapy to the spinal cord. Spinal cord tolerance is currently accepted as about 50 Gy in 1.8-2 Gy fractions. However, the effect of chemotherapy on cord tolerance is unclear. This issue is important, given the increasing use of chemotherapy in combination with radiotherapy. We describe the case of a 17-year-old boy with a right apical paraspinal Ewing's tumour in the neck treated with induction chemotherapy, high-dose chemotherapy (busulfan and melphalan) with peripheral stem-cell rescue and, 4 months later, radiotherapy to the primary tumour site (cervical cord received 50 Gy in 30 fractions). After a latent period of 4 months, he developed a progressive, severe and ultimately fatal radiation myelopathy, which we suggest was due to a synergistic interaction between the high-dose chemotherapy and the radiotherapy. The use of such chemotherapy regimens in Ewing's tumours should be carefully considered, particularly when radiotherapy encompassing the spinal cord is an essential component of management.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Busulfan/adverse effects , Melphalan/administration & dosage , Melphalan/adverse effects , Radiotherapy/adverse effects , Sarcoma, Ewing/drug therapy , Sarcoma, Ewing/radiotherapy , Spinal Cord Diseases/etiology , Adolescent , Bone Neoplasms/drug therapy , Bone Neoplasms/radiotherapy , Busulfan/administration & dosage , Combined Modality Therapy , Fatal Outcome , Humans , Male , Spinal Cord/radiation effects
8.
Br J Radiol ; 76 Spec No 2: S128-38, 2003.
Article in English | MEDLINE | ID: mdl-15572335

ABSTRACT

Studies of pharmacokinetics (which is what the body does to the drug) and pharmacodynamics (which is what the drug does to the body) are essential components of the modern process of cancer drug discovery and development. Defining the precise relationship between pharmacokinetics and pharmacodynamics is critical. It is especially important to establish a well understood pharmacological "audit trail" that links together all of the essential parameters of drug action, from the molecular target to the clinical effects. The pharmacological audit trail allows us to answer two absolutely crucial questions: (1) how much gets there; and (2) what does it do? During the pre-clinical drug discovery phase, it is essential that pharmacokinetic/pharmacodynamic (PK/PD) properties are optimized, so that the best candidate can be selected for clinical development. As part of contemporary mechanistic, hypothesis-testing clinical trials, construction of the pharmacological PK/PD audit trail facilitates rational decision-making. However, PK/PD endpoints frequently require invasive sampling of body fluids and tissues. Non-invasive molecular measurements, e.g. using MRI or spectroscopy, or positron emission tomography, are therefore very attractive. This review highlights the need for PK/PD endpoints in modern drug design and development, illustrates the value of PK/PD endpoints, and emphasises the importance of non-invasive molecular imaging in drug development. Examples cited include the use of PK/PD endpoints in the development of molecular therapeutic drugs such as the Hsp90 molecular chaperone inhibitor 17AAG, as well as the development of SR-4554 as a non-invasive probe for the detection of tumour hypoxia.


Subject(s)
Antineoplastic Agents , Diagnostic Imaging/methods , Neoplasms/metabolism , Rifabutin/analogs & derivatives , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Benzoquinones , HSP90 Heat-Shock Proteins/antagonists & inhibitors , Humans , Hypoxia/physiopathology , Lactams, Macrocyclic , Magnetic Resonance Imaging/methods , Magnetic Resonance Spectroscopy/methods , Neoplasms/drug therapy , Neoplasms/physiopathology , Nitroimidazoles , Positron-Emission Tomography/methods , Rifabutin/therapeutic use , Technology, Pharmaceutical/methods , Ultrasonography/methods
9.
Radiat Res ; 155(6): 837-46, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11352767

ABSTRACT

Hypoxia is important in tumor biology and therapy. This study compared the novel luminescence fiber-optic OxyLite sensor with the Eppendorf polarographic electrode in measuring tumor oxygenation. Using the relatively well-oxygenated P22 tumor, oxygen measurements were made with both instruments in the same individual tumors. In 24 air-breathing animals, pooled electrode pO(2) readings lay in a range over twice that of sensor pO(2(5min)) values (-3.2 to 80 mm Hg and -0.1 to 34.8 mm Hg, respectively). However, there was no significant difference between the means +/- 2 SE of the median pO(2) values recorded by each instrument (11.0 +/- 3.3 and 8.1 +/- 1.9 mm Hg, for the electrode and sensor respectively, P = 0.07). In a group of 12 animals treated with carbon monoxide inhalation to induce tumor hypoxia, there was a small but significant difference between the means +/- 2 SE of the median pO(2) values reported by the electrode and sensor (1.7 +/- 0.9 and 2.9 +/- 0.7 mm Hg, respectively, P = 0.009). A variable degree of disparity was seen on comparison of pairs of median pO(2) values from individual tumors in both air-breathing and carbon monoxide-breathing animals. Despite the differences between the sets of readings made with each instrument from individual tumors, we have shown that the two instruments provide comparable assessments of tumor oxygenation in groups of tumors, over the range of median pO(2) values of 0.6 to 28.1 mm Hg.


Subject(s)
Carcinosarcoma/metabolism , Neoplasms, Experimental/metabolism , Oxygen/metabolism , Animals , Biosensing Techniques , Carbon Monoxide/metabolism , Electrodes , Fiber Optic Technology , Luminescent Measurements , Optical Fibers , Polarography
SELECTION OF CITATIONS
SEARCH DETAIL
...